Leerink Partnrs Forecasts Sanofi's Q2 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY - Free Report) - Analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for Sanofi in a research report issued to clients and investors on Friday, April 25th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $0.99 per share for the quarter, up from their previous forecast of $0.93. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's Q3 2025 earnings at $1.76 EPS, FY2025 earnings at $4.56 EPS, FY2026 earnings at $5.07 EPS, FY2027 earnings at $5.21 EPS, FY2028 earnings at $5.64 EPS and FY2029 earnings at $6.19 EPS.

A number of other equities analysts have also commented on the stock. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of "Moderate Buy" and a consensus target price of $63.33.

Sanofi Stock Down 2.3 %

SNY stock opened at $52.32 on Monday. The business's fifty day moving average price is $54.53 and its two-hundred day moving average price is $52.05. The stock has a market capitalization of $132.17 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Hedge Funds Weigh In On Sanofi

A number of institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its stake in Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after acquiring an additional 5,091,304 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Sanofi during the 4th quarter worth approximately $135,933,000. Boston Partners lifted its stake in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after purchasing an additional 2,501,073 shares during the last quarter. Magnetar Financial LLC boosted its position in Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after buying an additional 1,705,148 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its stake in shares of Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock worth $45,850,000 after buying an additional 861,770 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.